The Scientific Core is designed to successfully recruit and monitor HCV-antibody-negative young injection drug users for HCV infection and to clinically characterize acute infection. Better understanding of spontaneous recovery of HCV infection is necessary to improve methods to prevent and treat chronic infection. A major limitation is the rare recognition of acute infection in humans. We have overcome this obstacle by following persons at risk for HCV infection monthly. By screening for HCV infection and careful monitoring of acutely infected persons, we have established an acute infection repository that has already been used by immunologists to advance our understanding of acute hepatitis C recovery and persistence. For this application, the Core aims to recruit and monitor HCV antibody negative young injection drug users, to clinically characterize acute infection when it occurs, and to establish and maintain an acute infection repository and distribute the resources to NIH funded investigators. By accomplishing these aims, the Clinical Core will make a major contribution to our understanding of hepatitis C recovery and achieve many of the objectives of RFA-AI-09-025. This cohort will allow us to prospectively follow subjects at risk for infection with blood testing including liver enzymes, HCV genotype, and HCV RNA levels and perform serial serum and lymphocyte collection and banking, allowing determination of the timing and outcome of infection and factors associated with outcome. This acute infection repository will distribute its resources for use in projects 1 and 2 as well as to other NIH funded investigators.

Public Health Relevance

The Scientific Core is designed to successfully recruit and monitor young injection drug users who have not yet been exposed to HCV infection. The purpose is to counsel them to avoid infection, but to acquire blood from those who do become infected in order to learn more about how HCV infection evades the immune system and persists.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-BP-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Bailey, Justin R; Wasilewski, Lisa N; Snider, Anna E et al. (2015) Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. J Clin Invest 125:437-47
Chattergoon, Michael A; Latanich, Rachel; Quinn, Jeffrey et al. (2014) HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog 10:e1004082
Osburn, William O; Snider, Anna E; Wells, Brittany L et al. (2014) Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology 59:2140-51
Grebely, Jason; Page, Kimberly; Sacks-Davis, Rachel et al. (2014) The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59:109-20
Duggal, Priya; Thio, Chloe L; Wojcik, Genevieve L et al. (2013) Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med 158:235-45
Cox, Andrea L; Thomas, David L (2013) Hepatitis C virus vaccines among people who inject drugs. Clin Infect Dis 57 Suppl 2:S46-50
Page, Kimberly; Osburn, William; Evans, Jennifer et al. (2013) Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. Clin Infect Dis 56:405-13
Osburn, W O; Levine, J S; Chattergoon, M A et al. (2013) Anti-inflammatory cytokines, pro-fibrogenic chemokines and persistence of acute HCV infection. J Viral Hepat 20:404-13
Liu, Lin; Fisher, Brian E; Thomas, David L et al. (2012) Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology 55:1684-91
Vickerman, Peter; Grebely, Jason; Dore, Gregory J et al. (2012) The more you look, the more you find: effects of hepatitis C virus testing interval on reinfection incidence and clearance and implications for future vaccine study design. J Infect Dis 205:1342-50

Showing the most recent 10 out of 13 publications